Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Morgan Stanley downgraded SPIE SA (EPA:SPIE) from Overweight to Equalweight on Thursday, while raising its price target to EUR52.50 from EUR47.50.
The downgrade comes after SPIE shares have surged approximately 80% year-to-date, with the gain attributed entirely to multiple expansion rather than earnings growth, according to Morgan Stanley.
Despite maintaining confidence in the company’s "multi-year compounding story and quality of management," the investment bank cited limited upside to consensus expectations over the next 12 months in the absence of additional mergers and acquisitions activity.
Morgan Stanley also noted that SPIE’s valuation multiples now fairly reflect the business’s value, suggesting the stock has reached an appropriate price level following its significant run-up.
The research firm indicated it does not see any obvious positive catalysts on the horizon that could drive another significant multiple re-rating for SPIE shares in the short term.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.